- ►nejm.org LJ Rubin, DB Badesch, RJ Barst, N Galie, CM … - The New England journal of medicine, 2002 - nejm.highwire.org Methods In this double-blind, placebo-controlled study, we randomly assigned 213
patients with pulmonary arterial hypertension (primary or associated with
connective-tissue disease) to receive placebo or to receive 62.5 mg of ... Cited by 1390 - Related articles - BL Direct - All 17 versions
- ►onlinejacc.org G Simonneau, N Galiè, LJ Rubin, D Langleben … - Journal of the American College of Cardiology, 2004 - Elsevier In 1998, during the Second World Symposium on Pulmonary Hypertension (PH) held
in Evian, France, a clinical classification of PH was proposed. The aim of the
Evian classification was to individualize different categories sharing ... Cited by 970 - Related articles - BL Direct - All 16 versions
H Olschewski, G Simonneau, N Galie, T … - New England Journal of Medicine, 2002 - content.nejm.org Methods We compared repeated daily inhalations of 2.5 or 5.0 µg of iloprost
(six or nine times per day; median inhaled dose, 30 µg per day) with inhalation
of placebo. A total of 203 patients with selected forms of severe pulmonary ... Cited by 845 - Related articles - BL Direct - All 19 versions
- ►ucsd.edu [PDF] RN Channick, G Simonneau, O Sitbon, IM … - The Lancet, 2001 - Elsevier In patients given bosentan, the distance walked in 6 min improved by 70 m at 12
weeks compared with baseline, whereas it worsened by 6 m in those on placebo
(difference 76 m [95% CI 12-139], p=0<021). The improvement was maintained ... Cited by 838 - Related articles - BL Direct - All 11 versions
- ►171.66.122.149 G Simonneau, RJ Barst, N Galie, R Naeije, S … - American journal of respiratory and critical care …, 2002 - 171.66.122.149 Pulmonary arterial hypertension is a life-threatening disease for which
continuous intravenous prostacyclin has proven to be effective. However, this
treatment requires a permanent central venous catheter with the associated ... Cited by 629 - Related articles - BL Direct - All 9 versions
- ►shouxi.net M Humbert, O Sitbon, G Simonneau - The New England journal of medicine, 2004 - nejm.highwire.org Pulmonary arterial hypertension is a disease of the small pulmonary arteries
that is characterized by vascular proliferation and remodeling. 1 , 2 It results
in a progressive increase in pulmonary vascular resistance and, ultimately, ... Cited by 586 - Related articles - BL Direct - All 15 versions
- ►ahajournals.org VV McLaughlin, A Shillington, S Rich - Circulation, 2002 - Am Heart Assoc Methods and Results— One hundred sixty-two consecutive patients diagnosed with
PPH and treated with epoprostenol were followed for a mean of 36.3 months
(median, 31 months). Data including functional class, exercise tolerance, ... Cited by 549 - Related articles - BL Direct - All 7 versions
- ►onlinejacc.org N Galie, M Humbert, JL Vachiery, CD Vizza, M … - Journal of the American College of Cardiology, 2002 - Elsevier Patients treated with beraprost improved exercise capacity and symptoms. The
difference between treatment groups in the mean change of 6-min walking distance
at week 12 was 25.1 m (95% confidence interval [CI]: 1.8 to 48.3, P = ... Cited by 342 - Related articles - BL Direct - All 13 versions
- ►onlinejacc.org RJ Barst, M McGoon, V McLaughlin, V Tapson, … - Journal of the American College of Cardiology, 2003 - Elsevier A total of 116 patients with World Health Organization (WHO) functional class II
or III primary pulmonary hypertension or PAH related to either collagen vascular
diseases or congenital systemic to pulmonary shunts were enrolled. Patients ... Cited by 306 - Related articles - BL Direct - All 5 versions
- ►westhertshospitals.nhs.uk [PDF] JR Runo, JE Loyd - The Lancet, 2003 - Elsevier Primary pulmonary hypertension (PPH) is a rare disorder characterised by raised
pulmonary-artery pressure in the absence of secondary causes. Precapillary
pulmonary arteries are affected by medial hypertrophy, intimal fibrosis, ... Cited by 300 - Related articles - All 13 versions
